Tagged with Global

Global Although the COVID-19 pandemic and the subsequent rush to develop diagnostics, therapeutics, and vaccines dominated the global headlines in 2020, PharmaBoardroom’s network of industry insiders contributed pieces across a broad swathe of topics this year. See below for a selection of articles ranging from cross country pricing collaborations to AI…

Global 2020 was a challenging year globally, but one in which the importance of the healthcare and life sciences sector was underlined like never before. Despite lockdowns and travel restrictions, PharmaBoardroom still managed to talk to key industry stakeholders from across the world helping shape the future of global health. Featured…

Global The top 10 most-read interviews on PharmaBoardroom in 2020 represents the broad geographic scope we have had in the past year. From Mexico to Morocco and Romania to Riyadh, these local insights help give a more well-rounded global picture of our industry today.   1. Bill Sibold, Executive VP, Sanofi…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this month, three industry leaders spoke about innovative reimbursement models like ‘pay-for-performance’ agreements and the implementation challenges of such initiatives. The session was moderated by FT reporter Donato Mancini and saw the participation of Novartis Oncology president Dr Susanne Schaffert; bluebird…

Global Following the recent news of Remegen’s massive USD 515 million IPO in November 2020, we bring you the seven biggest biotech IPOs this year. Notably, six of the seven companies are from China, pointing to the massive growth of the Chinese biotech market. Made with Visme Infographic Maker

Global Epidemiologist John-Arne Røttingen has had a long and distinguished career in both academia and industry, including stints at Oslo, Oxford and Harvard universities, as well as helping coordinate the WHO’s response to the West African Ebola virus epidemic of 2013-2016 and being the founding CEO of the Coalition for Epidemic…

Global Sanofi CEO Paul Hudson ignited a heated debate around vaccine nationalism earlier this year when he suggested that the US, having made the biggest initial investment in Sanofi’s COVID-19 vaccine development, should have the first call on any vaccine that the firm was subsequently able to bring to market. In…

Global During the FT Global Pharmaceutical and Biotechnology Conference last week, GSK global vaccines president Roger Connor shared some of his insights regarding the reorganization of GSK’s Consumer Health, Pharmaceuticals and Vaccines business units, their pandemic adjuvant system technology, and their – and the industry’s overall – commitment to COVID-19 vaccine…

Global Ipsen CEO David Loew took aim at the lip service often paid to the notion of ‘patient-centricity’ in pharma in conversation at the FT’s Global Pharmaceutical and Biotechnology Conference last week and explained how the industry should take on a wider and deeper role in shaping healthcare systems, thereby creating…

Global During the FT Global Pharmaceutical and Biotechnology Conference earlier this week, four Big Pharma and biotech executives spoke about the changing power structure of the industry and the factors driving the evolution of the pharma innovation model. The session was moderated by Deloitte global life sciences and health care leader…

Global Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park highlights key takeaways from the BIOJapan 2020 conference on why San Diego offers a good example of what it takes to be a leader in the innovative life science sector.   Over the past two decades, drug discovery has undergone…

Global COVID-19 has drawn global attention to the sorry state of funding and R&D investment in vaccine development and pandemic prevention, but other previously neglected areas of health research are also now entering the spotlight. One of these underfunded areas is mental health and neurological disorders, leading a global group of…